Tenenbaum A - Search Results

1

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.

Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Tenenbaum A, et al. Arch Intern Med. 2005 May 23;165(10):1154-60. doi: 10.1001/archinte.165.10.1154. Arch Intern Med. 2005. PMID: 15911729 Clinical Trial.

2

Does participation in a long-term clinical trial lead to survival gain for patients with coronary artery disease?

Tenenbaum A, Motro M, Fisman EZ, Boyko V, Mandelzweig L, Shotan A, Behar S. Tenenbaum A, et al. Am J Med. 2002 May;112(7):545-8. doi: 10.1016/s0002-9343(02)01074-4. Am J Med. 2002. PMID: 12015246

3

Functional class in patients with heart failure is associated with the development of diabetes.

Tenenbaum A, Motro M, Fisman EZ, Leor J, Freimark D, Boyko V, Mandelzweig L, Adler Y, Sherer Y, Behar S. Tenenbaum A, et al. Am J Med. 2003 Mar;114(4):271-5. doi: 10.1016/s0002-9343(02)01530-9. Am J Med. 2003. PMID: 12681453

4

Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease.

Goldenberg I, Jonas M, Tenenbaum A, Boyko V, Matetzky S, Shotan A, Behar S, Reicher-Reiss H; Bezafibrate Infarction Prevention Study Group. Goldenberg I, et al. Among authors: tenenbaum a. Arch Intern Med. 2003 Oct 27;163(19):2301-5. doi: 10.1001/archinte.163.19.2301. Arch Intern Med. 2003. PMID: 14581249

5

Functional capacity impairment in patients with coronary artery disease: prevalence, risk factors and prognosis.

Tenenbaum A, Motro M, Fisman EZ, Leor J, Boyko V, Mandelzweig L, Behar S. Tenenbaum A, et al. Cardiology. 2003;100(4):207-15. doi: 10.1159/000074814. Cardiology. 2003. PMID: 14713732

6

Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.

Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. Tenenbaum A, et al. Circulation. 2004 May 11;109(18):2197-202. doi: 10.1161/01.CIR.0000126824.12785.B6. Epub 2004 May 3. Circulation. 2004. PMID: 15123532 Clinical Trial.

7

Is hypoglycaemia a marker for increased long-term mortality risk in patients with coronary artery disease? An 8-year follow-up.

Fisman EZ, Motro M, Tenenbaum A, Leor J, Boyko V, Mandelzweig L, Sherer Y, Adler Y, Behar S. Fisman EZ, et al. Among authors: tenenbaum a. Eur J Cardiovasc Prev Rehabil. 2004 Apr;11(2):135-43. doi: 10.1097/01.hjr.0000124326.85096.ec. Eur J Cardiovasc Prev Rehabil. 2004. PMID: 15187817

8

Macrovascular complications of metabolic syndrome: an early intervention is imperative.

Tenenbaum A, Motro M, Schwammenthal E, Fisman EZ. Tenenbaum A, et al. Int J Cardiol. 2004 Nov;97(2):167-72. doi: 10.1016/j.ijcard.2003.07.033. Int J Cardiol. 2004. PMID: 15458679 Review.

9

Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.

Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D, Leor J, Boyko V, Schwammenthal E, Behar S. Tenenbaum A, et al. Eur Heart J. 2005 Oct;26(19):2032-8. doi: 10.1093/eurheartj/ehi310. Epub 2005 May 4. Eur Heart J. 2005. PMID: 15872029 Clinical Trial.

10

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.

Tenenbaum A, Motro M, Fisman EZ. Tenenbaum A, et al. Cardiovasc Diabetol. 2005 Sep 16;4:14. doi: 10.1186/1475-2840-4-14. Cardiovasc Diabetol. 2005. PMID: 16168052 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

323 results

Search Page

Filters